Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Effect of Cimetidine and Phenobarbital on Metabolite Kinetics of Omeprazole in Rats

  • Park Eun-Ja (College of Pharmacy, and Institute of Bioequivalence and Bridging Study, Chonnam National University) ;
  • Cho Hea-Young (Clinical Trial Center, Chonnam National University) ;
  • Lee Yong-Bok (College of Pharmacy, and Institute of Bioequivalence and Bridging Study, Chonnam National University)
  • Published : 2005.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Omeprazole (OMP) is a proton pump inhibitor used as an oral treatment for acid-related gastrointestinal disorders. In the liver, it is primarily metabolized by cytochrome P-450 (CYP450) isoenzymes such as CYP2C19 and CYP3A4. 5-Hyroxyomeprazole (5-OHOMP) and omeprazole sulfone (OMP-SFN) are the two major metabolites of OMP in human. Cimetidine (CMT) inhibits the breakdown of drugs metabolized by CYP450 and reduces, the clearance of coad-ministered drug resulted from both the CMT binding to CYP450 and the decreased hepatic blood flow due to CMT. Phenobarbital (PB) induces drug metabolism in laboratory animals and human. PB induction mainly involves mammalian CYP forms in gene families 2B and 3A. PB has been widely used as a prototype inducer for biochemical investigations of drug metabolism and the enzymes catalyzing this metabolism, as well as for genetic, pharmacological, and toxicological investigations. In order to investigate the influence of CMT and PB on the metabolite kinetics of OMP, we intravenously administered OMP (30 mg/kg) to rats intraperitoneally pretreated with normal saline (5 mL/kg), CMT (100 mg/kg) or PB (75 mg/kg) once a day for four days, and compared the pharmacokinetic parameters of OMP. The systemic clearance ($CL_{t}$) of OMP was significantly (p<0.05) decreased in CMT-pretreated rats and significantly (p<0.05) increased in PB-pretreated rats. These results indicate that CMT inhibits the OMP metabolism due to both decreased hepatic blood flow and inhibited enzyme activity of CYP2C19 and 3A4 and that PB increases the OMP metabolism due to stimulation of the liver blood flow and/or bile flow, due not to induction of the enzyme activity of CYP3A4.

Keywords

References

  1. Andersson, T., Miners, J. O., Veronese, M. E., and Birkett, D. J., Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol., 37, 597-604 (1994) https://doi.org/10.1111/j.1365-2125.1994.tb04310.x
  2. Andersson, T., Miners, J. O., Veronese, M. E., Tassaneeyakul, W., Meyer, U. A., and Birkett, D. J., Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol., 36, 521-530 (1993) https://doi.org/10.1111/j.1365-2125.1993.tb00410.x
  3. Badyal, D. K. and Dadhich, A. P., Cytochrome p450 and drug interactions. Indian J. Pharmacol., 33, 248-259 (2001)
  4. Black, J. W., Histamine $H_2$-receptor antagonists and gastric acid secretion-A progress report. Klin. Wochenschr., 54, 911-914 (1976) https://doi.org/10.1007/BF01469004
  5. Branch, R. A., Shand, D. G., Wilkinson, G. R., and Nies, A. S., Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey; Relative contributions of enzyme induction and increased hepatic blood flow. J. Clin. Invest., 53, 1101 (1974)
  6. Carlile, D. J., Zomorodi, K., and Houston, J. B., Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver studies with induced livers involving diazepam. Drug Metab. Dispos., 25, 903-911 (1997)
  7. Cheng, F. C., Ho, Y.. F, Hung, L. C., Chen, C. F., and Tsai, T.H., Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and highperformance liquid chromatography. J. Chromatogr. A, 949, 35-42 (2002) https://doi.org/10.1016/S0021-9673(01)01225-0
  8. Gabrielsson, J. and Weiner, D., Pharmacokinetic and pharma-codynamic data analysis: concepts & applications 3rd edition, Apotekarsocieteten, Stockholm, (2000)
  9. Howden, C. W., Clinical pharmacology of omeprazole, Clin. Pharmacokinet., 20, 38-49 (1991) https://doi.org/10.2165/00003088-199120010-00003
  10. Kakizaki, S., Yamamoto, Y., Ueda, K., Moore, R., Sueyoshi, T., and Negishi, M., Phenobarbital induction of drug/steroidmetabolizing enzymes and nuclear receptor CAR. Biochim. Biophy. Acta, 1619, 239-242 (2003) https://doi.org/10.1016/S0304-4165(02)00482-8
  11. Knodell, R. G., Holtzmann, D. L., Crankshaw, D. L., Steele, N. M., and Stanley, L. N., Drug metabolism by rat and human microsomes in response to interaction with $H_2$-receptor. Gastroenterology, 82, 84-88 (1982)
  12. Kobayashi, K., Chiba, K., Sohn, D. R., Kato, Y., and Ishizaki, T., Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymercoated $C_{18}$ column. J. Chromatogr., 579, 299-305 (1992) https://doi.org/10.1016/0378-4347(92)80395-7
  13. Levy, R. H., Hachad, H., Yao, C., and Ragueneau-Majlessi, I., Relationship between extent of inhibition and inhibitor dose, literature evaluation based on the metabolism and transport drug interaction database. Curr. Drug Metab., 4, 371-380 (2003) https://doi.org/10.2174/1389200033489325
  14. Marc, N., Galisteo, M., Lagadic-Gossmann, D., Fautrel, A., Joannard, F., Guillouzo, A., and Corcos, L., Regulation of phenobarbital induction of the cytochrome P450 2b9/10 genes in primary mouse hepatocyte culture. Eur. J. Biochem., 267, 963-970 (2000) https://doi.org/10.1046/j.1432-1327.2000.01083.x
  15. Mino, K., Watanabe, J., and Kanamura, S., Effect of 3-methylcholanthrene administration on expression of cytochrome P450 isoforms induced by phenobarbital in rat hepatocytes. J. Histochem. Cytochem., 46, 1151-1160 (1998) https://doi.org/10.1177/002215549804601007
  16. Petersen, K. U., Omeprazole and the cytochrome P450 system. Aliment. Pharmacol. Ther., 9, 1-9 (1994)
  17. Regardh, C. G., Gabrielsson, M., Hoffman, K. J., Lofberg, I., and Skanberg, I., Pharmacokinetics and metabolism of omeprazole in animals and man. Scan. J. Gastroenterol. Suppl., 108, 79-94 (1985)
  18. Shiga, T., Hashiguchi, M., Urae, A., Kasanuki, H., and Rikihisa, T., Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin. Pharmacol. Ther., 67, 222-228 (2000) https://doi.org/10.1067/mcp.2000.104018
  19. Sudjana-Sugiaman, E., Eggertsen, G., and Bjorkhem, I., Stimulation of HMG-CoA reductase as a consequence of phenobarbital-induced primary stimulation of cholesterol 7 alpha-hydroxylase in rat liver. J. Lipid Res., 35, 319-327 (1994)
  20. Szutowski, M.M., Zalewska, K., Jadczak, M., and Marek, M., In vivo effect of diallyl sulfide and cimetidine on phenacetin metabolism and bioavailability in rat. Acta Biochim. Pol., 49, 249-256 (2002)
  21. Waxman, D. J. and Walsh, C., Phenobarbital-induced rat liver cytochrome P-450. Purification and characterization of two closely related isozymic forms. J. Bio. Chem., 257, 10446-10454 (1982)
  22. Wilde, M. I. and McTavish, D., Omeprazole: An update of its pharmacology and therapeutic use in acid-related disorders. Drugs, 48, 91-131 (1994) https://doi.org/10.2165/00003495-199448010-00008
  23. $WinNonlin^{TM}$ User's Guide Ver. 3.0, Pharsight Corp., Mountain View, CA, U.S.A. (1999)
  24. Wintrobe, M. M., Lee, G. R., and Boggs, D. R., Clinical Hematology 7th ed. Lea & Febiger, Philadelphia (1974)
  25. Yamano, K., Yamamoto, K., Katashima, M., Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y., and Iga, T., Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivolin vitro absorption, distribution, and metabolism data. Drug Metab. Dispos., 29,443-452 (2001)